Key Takeaways
- WHO confirmed an Andes hantavirus (ANDV) cluster aboard the MS Hondius cruise ship in May 2026 — the first outbreak linked to eco-tourism travel from Argentina.
- ANDV is the only hantavirus with confirmed person-to-person transmission, making rapid serological identification critical for outbreak control.
- Hantaviruses cause two distinct clinical syndromes: HFRS (Old World, renal) and HPS/HCPS (New World, pulmonary), with no cross-protective vaccines.
- The nucleocapsid (N) protein is the optimal antigen for broad-spectrum hantavirus IgM/IgG serology; Gn glycoprotein is used for species-level differentiation.
- A well-designed hantavirus serological assay platform — ELISA, CLIA, or LFA — requires carefully selected recombinant antigens, validated antibody reagents, and an IgM-capture format for early detection.
1. The MS Hondius Outbreak: What Happened
On May 4, 2026, the World Health Organization published Disease Outbreak News report DON599, confirming a cluster of hantavirus infections linked to a cruise voyage aboard the MS Hondius, an expedition ship operated by Oceanwide Expeditions. The vessel had departed Argentina on April 1, 2026, carrying passengers on a South Atlantic eco-tourism itinerary focused on wildlife observation — including visits to bird colonies and coastal habitats in Argentina and Chile.
The first two patients reported symptoms after returning from shore excursions in areas known to harbour Oligoryzomys longicaudatus — the long-tailed pygmy rice rat, the primary reservoir of Andes virus (ANDV). Initial symptoms were unremarkable: low-grade fever and gastrointestinal discomfort that both crew and passengers attributed to food poisoning. Within days, however, both patients deteriorated rapidly, developing pneumonia, acute respiratory distress syndrome (ARDS), and cardiogenic shock — the hallmark clinical trajectory of Hantavirus Cardiopulmonary Syndrome (HCPS).
By May 10, 2026, a total of 8 confirmed cases and 3 deaths had been reported. The ship was anchored off the coast of Cape Verde while an international medical response team conducted testing and contact tracing. WHO Director-General Dr. Tedros Adhanom Ghebreyesus stated that the overall public health risk was assessed as low at the global level, noting that ANDV's person-to-person transmission, while confirmed, is limited and highly dependent on prolonged close contact.
Why this outbreak matters diagnostically: Most hantavirus clusters occur in rural settings with low diagnostic capacity. An outbreak aboard a cruise ship — a closed, mobile environment carrying passengers from multiple countries — creates an urgent need for rapid, portable, and reliable serological tools that can function outside a reference laboratory.
This is not the first time ANDV has caused a multi-person cluster. In 1996, an outbreak in El Bolsón, Argentina was the first documented evidence of ANDV person-to-person spread. In 2018, a larger cluster in the small town of Epuyen, Argentina infected 34 people and killed 11, enabling scientists to reconstruct a full transmission chain. The 2026 MS Hondius outbreak is notable for two reasons: it occurred aboard an international vessel, and the index cases were eco-tourists — a reminder that wildlife-adjacent recreation carries zoonotic risks that conventional travel health frameworks often underestimate.
2. Hantavirus Biology: The Essentials
2.1 Taxonomy and Genome Architecture
Hantaviruses belong to the family Hantaviridae, genus Orthohantavirus. They are enveloped, negative-sense, single-stranded RNA viruses with a tripartite (three-segment) genome:
- S segment — encodes the nucleocapsid (N) protein, which encapsidates the viral RNA. The N protein is the most abundant viral antigen and the primary target for serological assays.
- M segment — encodes the envelope glycoproteins Gn and Gc, which mediate receptor binding (primarily β3 integrins) and membrane fusion. Gn carries the dominant neutralizing epitopes and is species-specific.
- L segment — encodes the RNA-dependent RNA polymerase (RdRp) responsible for viral replication and transcription.
Unlike many RNA viruses, hantaviruses do not encode a nonstructural protein and do not lyse their natural rodent reservoir hosts. This remarkable host-tolerance is the key to the virus's ecological success.
2.2 Natural Reservoir and Transmission
Each hantavirus species co-evolved with a specific rodent host, in which it establishes a persistent, lifelong, asymptomatic infection. Infected rodents shed virus in urine, feces, and saliva — sometimes for months. Humans are incidental dead-end hosts, infected by:
- Inhalation of infectious aerosols from dried rodent excreta (the dominant route, accounting for the majority of cases)
- Direct contact with contaminated materials entering through broken skin or mucous membranes
- Rodent bites (rare)
- Person-to-person (confirmed only for ANDV; mechanism involves respiratory secretions during the cardiopulmonary phase)
Environmental stability: Hantaviruses have limited survival outside a host. They are rapidly inactivated by UV light, desiccation, and standard disinfectants (1% sodium hypochlorite, 70% ethanol, formaldehyde). This makes decontamination straightforward but also means environmental sampling is rarely diagnostic.
2.3 Two Diseases, Two Continents
Hantaviruses cause two clinically distinct syndromes depending on geographic origin:
| Feature | HFRS (Old World) | HPS / HCPS (New World) |
|---|---|---|
| Full name | Hemorrhagic Fever with Renal Syndrome | Hantavirus Pulmonary / Cardiopulmonary Syndrome |
| Key viruses | Hantaan (HTNV), Seoul (SEOV), Puumala (PUUV), Dobrava (DOBV) | Sin Nombre (SNV), Andes (ANDV), Black Creek Canal |
| Primary reservoir | Apodemus spp., Rattus spp., Myodes spp. | Peromyscus spp., Oligoryzomys spp. |
| Target organ | Kidneys (acute tubular necrosis, proteinuria, hematuria) | Lungs (non-cardiogenic pulmonary edema, ARDS) |
| Case fatality rate | 0.1–15% (HTNV up to 15%) | 30–40% (SNV); 12–25% (ANDV) |
| Distribution | Asia, Europe; China highest burden globally | North and South America |
| Vaccine available | Yes (bivalent inactivated, China; Korea) | No licensed vaccine |
| Person-to-person transmission | Not documented | Confirmed for ANDV only |
Pathogenesis in both syndromes is driven not by direct viral cytotoxicity but by an immune-mediated endothelial dysfunction. The virus infects endothelial cells without lysing them; instead, the resulting immune response — particularly CD8+ T cell activity and pro-inflammatory cytokine release (including elevated IL-6 and TNF-α) — causes capillary leakage in the target organ. This "cytokine storm" physiology explains why patients deteriorate rapidly once the immune phase begins, and why the therapeutic window for intervention is narrow.
2.4 Clinical Course and Key Diagnostic Window
The incubation period for hantavirus ranges from 2 to 4 weeks (occasionally up to 8 weeks for ANDV). Clinical illness proceeds through distinct phases:
- Febrile phase (days 1–5): Fever, myalgia, headache, GI symptoms — clinically indistinguishable from influenza or food poisoning. Viral RNA is detectable by PCR; antibodies have not yet appeared.
- Critical phase (days 4–10): Pulmonary edema (HPS) or renal impairment (HFRS). IgM becomes detectable from day 4–7 — this is the earliest serological window and the key target for rapid testing.
- Recovery phase: IgG rises and persists for years; IgM declines over weeks to months.
3. How Is Hantavirus Diagnosed? Current Methods
3.1 RT-PCR: Early but Infrastructure-Intensive
Reverse transcription PCR targeting the S or M segment is the most sensitive method during the febrile phase, when viral RNA is present in blood. Sensitivity exceeds 95% in the first 3–5 days of illness. However, viremia clears rapidly once the immune response is established — often before patients present to hospital with severe disease. RT-PCR also requires BSL-3 containment for ANDV work, a significant barrier in resource-limited settings and during travel-related outbreaks far from reference laboratories.
3.2 Serology: The Clinical Standard
Because most patients present after the viremic window has closed, serology is the practical backbone of hantavirus diagnosis. IgM detection at or near symptom onset has a sensitivity of approximately 96% and specificity of 97–99% using validated ELISA platforms. The primary serological targets are:
- IgM: Present from day 4–7, peaks at 1–4 weeks. Detectable IgM at presentation is essentially diagnostic of acute infection.
- IgG: Appears shortly after IgM, persists lifelong. Used for seroprevalence studies, retrospective diagnosis, and confirming past exposure.
- Neutralizing antibodies (Plaque Reduction Neutralization Test, PRNT): Species-specific confirmation requiring live virus; reserved for reference labs and epidemiological investigation.
3.3 Antigen Detection
Antigen-based rapid tests (analogous to influenza or SARS-CoV-2 antigen RDTs) remain underdeveloped for hantavirus. Antigen levels in peripheral blood are low, and the window of detectable antigenemia is short. Current research focuses on N protein detection in early-phase samples. This is an area where sensitivity engineering — ultrasensitive immunoassay platforms, signal amplification — will be critical to making antigen detection clinically viable.
4. Serological Test Development: A Strategy for Hantavirus IgM/IgG Assays
For IVD developers, hantavirus represents a technically tractable yet commercially underserved diagnostic opportunity. The following framework outlines the key decisions at each stage of assay development.
4.1 Antigen Selection: N Protein vs. Gn Glycoprotein
The choice of antigen determines the assay's breadth of detection and species specificity:
| Antigen | Cross-reactivity | Expression Platform | Best Use Case |
|---|---|---|---|
| N protein (nucleocapsid) | Broad (50–75% AA identity across species) | E. coli (high yield, easy purification) | Genus-level screening; HFRS/HPS triage |
| Gn ectodomain | Species-specific (neutralizing epitopes) | Mammalian (HEK293, CHO) or baculovirus | Species differentiation; confirmatory testing |
| Gc ectodomain | Partial cross-reactivity | Mammalian or baculovirus | Research; neutralization escape studies |
| Multiplex N-protein panel (HTNV + SEOV + ANDV) | Species-resolved via differential signal | Multiple E. coli expression runs | Outbreak investigation; traveler screening |
Recommendation for a primary assay: Begin with the N protein of the species most relevant to your target market. For Asia (HFRS surveillance), use HTNV or SEOV N protein. For South America or travel medicine, use ANDV N protein. A broad-spectrum assay can combine two or three N proteins on the same plate to maximize sensitivity without sacrificing specificity beyond clinical utility.
4.2 Recombinant N Protein Expression
The N protein is highly amenable to prokaryotic expression:
- E. coli expression: Codon-optimized N protein gene (45–50 kDa) expressed in BL21(DE3) with His-tag → IPTG induction → inclusion body solubilization → Ni-NTA purification → refolding. Yields of 5–20 mg/L are routinely achievable. Key QC metrics: purity >95% by SDS-PAGE, correct molecular weight by Western blot with reference antisera, reactivity with confirmed-positive patient panels.
- Immunoreactivity validation: Test each N protein lot against a panel of confirmed HFRS/HPS sera (IgM and IgG positive), negative healthy donor sera, and cross-reactive flavivirus or orthomyxovirus sera to establish specificity baselines.
- Coating concentration optimization: Typical ELISA coating ranges 1–5 µg/mL in carbonate buffer (pH 9.6), overnight at 4°C. Optimize with a titration matrix against a dilution series of reference positive sera.
4.3 Assay Format Selection
| Format | Target | Sensitivity | Time to Result | Setting |
|---|---|---|---|---|
| Indirect ELISA | IgM or IgG | High (reference method) | 3–4 hours | Reference laboratory |
| IgM-capture ELISA (µ-capture) | IgM (early acute) | Highest for early IgM | 3–4 hours | Reference / hospital lab |
| CLIA (chemiluminescent) | IgM + IgG | Very high (automated) | 30–60 min | Hospital lab, automated analyzer |
| LFA (lateral flow) | IgM + IgG (dual line) | Moderate–High | 15–20 min | Point-of-care / field use |
| FIA (fluorescent immunoassay) | IgM + IgG | High | 15–20 min | POC with reader (e.g., SP-10 FIA) |
For outbreak response and travel medicine: A dual IgM/IgG lateral flow assay is the most deployable format. Conjugate the N protein to colloidal gold; capture anti-human IgM and anti-human IgG on separate test lines; include a biotinylated anti-species antibody on the control line. A reactive IgM line in a patient with compatible symptoms and travel history is sufficient to trigger isolation precautions while confirmatory testing proceeds.
4.4 IgM-Capture Format: Why It Matters for Early Detection
In a conventional indirect ELISA, N protein is coated on the plate and patient serum is added directly. Rheumatoid factor (RF) and cross-reactive IgG can compete with IgM for binding sites, reducing IgM sensitivity in early samples. The IgM-capture (µ-capture) format avoids this by:
- Coating the plate with anti-human IgM (µ-chain specific) antibody
- Capturing total IgM from patient serum
- Adding biotinylated or HRP-conjugated N protein antigen to detect hantavirus-specific IgM
- Quantifying signal with streptavidin-HRP and TMB substrate
This format is 20–40% more sensitive for early acute IgM compared to indirect ELISA, making it the preferred design for outbreak settings where patients present on day 4–6 of illness.
4.5 Key Technical Challenges
- Cross-reactivity management: N proteins share 50–75% identity across hantavirus species. An HTNV N protein ELISA will detect ANDV infections (and vice versa) at reduced sensitivity. This is clinically acceptable for triage but must be declared in the IFU. Use WHO reference sera to establish cross-reactivity matrices during validation.
- IgM prozone effect: Very high IgM concentrations can cause false negatives in sandwich formats. Include a dilution series (1:100, 1:200, 1:400) or use an auto-dilution step in automated CLIA systems.
- Antigen stability: Recombinant N protein can aggregate over time, particularly after freeze-thaw cycles. Optimize storage in PBS + 5% trehalose + 0.1% BSA at −20°C; validate lot-to-lot consistency with reference OD values from a retained positive serum panel.
- Species-specific confirmation: For epidemiological identification of which hantavirus species caused an outbreak (critical for public health response), include a secondary confirmatory assay using Gn ectodomains from multiple species, or refer to PRNT at a BSL-3 reference facility.
Developing a Hantavirus Serological Assay?
Sekbio specializes in recombinant antigen production and antibody reagent development for infectious disease diagnostics. Our protein expression platform can produce validated, high-purity nucleocapsid antigens for ELISA and LFA development. We also supply antibody pairs and blocking reagents that help eliminate interference in complex serum matrices — a critical requirement when developing IgM assays for early acute infection.
Contact Our Technical Team5. Surveillance Context: Hantavirus Around the World
The MS Hondius outbreak is a high-profile reminder of a global diagnostic gap. Hantavirus surveillance infrastructure is uneven:
- China: The highest absolute burden country for HFRS. HTNV and SEOV circulate endemically. A bivalent inactivated vaccine (covering HTNV + SEOV) has been available since the 1990s and is offered free in high-incidence counties. In 2024, China recorded 4,259 confirmed cases and 12 deaths (Chinese NHC Statistical Bulletin). No ANDV or HPS cases have been documented in China.
- Europe: Puumala virus (PUUV) causes a mild HFRS (nephropathia epidemica) in Scandinavia and Central Europe. Dobrava virus causes a more severe form in the Balkans. PUUV serology is routinely performed in endemic countries.
- Americas: SNV is the dominant HPS agent in North America; ANDV dominates in southern South America. Surveillance is fragmented and often limited to confirmed severe cases, meaning the true incidence of mild infection is unknown.
- Eco-tourism travelers: Represent an underdiagnosed population. Physicians in non-endemic countries rarely consider hantavirus in the differential — this outbreak may accelerate awareness and demand for travel clinic serology panels.
Frequently Asked Questions
What is Andes hantavirus and why can it spread person-to-person?
Andes virus (ANDV) is a South American hantavirus that causes Hantavirus Cardiopulmonary Syndrome (HCPS). Unlike nearly all other hantaviruses, ANDV is the only species with confirmed evidence of limited human-to-human transmission. High viral loads in respiratory secretions during the cardiopulmonary phase appear to enable close-contact spread — particularly among household members, intimate partners, and unprotected healthcare workers. Standard infection control precautions (contact + droplet) are sufficient to break transmission chains.
What is the best diagnostic test for hantavirus infection?
Test selection depends on disease phase. RT-PCR targeting the S or M segment is the most sensitive method in the first 3–5 days of fever (viremic phase), but requires BSL-3 infrastructure and is often negative by the time patients present with severe disease. Serology — IgM/IgG ELISA or rapid lateral flow assay — is the practical clinical standard from day 4–7 onward. A positive IgM in a patient with compatible symptoms and epidemiological exposure is diagnostic. For species-level confirmation (distinguishing ANDV from HTNV, SEOV, etc.), a plaque reduction neutralization test (PRNT) at a reference laboratory is required.
What antigen is used in hantavirus serological tests?
The nucleocapsid (N) protein is the dominant antigen in hantavirus serology. It is highly immunogenic, abundantly expressed during infection, and readily produced as a recombinant protein in E. coli. A critical feature is its broad cross-reactivity: N proteins across hantavirus species share 50–75% amino acid identity, so an HTNV N-protein ELISA will detect antibodies raised against ANDV (and vice versa), enabling a single assay to screen for genus-level exposure. For species-specific differentiation — important for epidemiological investigation — the Gn glycoprotein ectodomain, which carries the primary neutralizing epitopes, is used instead.
What is the difference between HFRS and HPS/HCPS?
Hemorrhagic Fever with Renal Syndrome (HFRS) is caused by Old World hantaviruses (Hantaan, Seoul, Puumala, Dobrava) and primarily damages the kidneys, causing proteinuria, hematuria, and acute renal failure, with case fatality rates of 0.1–15%. Hantavirus Pulmonary/Cardiopulmonary Syndrome (HPS/HCPS) is caused by New World hantaviruses (Sin Nombre, Andes) and targets the lungs, causing non-cardiogenic pulmonary edema and cardiogenic shock, with case fatality rates of 30–40%. Both syndromes result from immune-mediated endothelial dysfunction rather than direct viral cytotoxicity, which is why cytokine markers such as IL-6 and TNF-α are elevated in severe cases.
Does China have hantavirus, and is there a vaccine?
Yes. China has one of the world's highest burdens of hantavirus disease, with Hantaan virus (HTNV) circulating via wild field mice and Seoul virus (SEOV) via urban rats. Hemorrhagic fever with renal syndrome (known as epidemic hemorrhagic fever in Chinese) is a Class B notifiable disease. In 2024, China reported 4,259 cases and 12 deaths (NHC Statistical Bulletin). A bivalent inactivated vaccine covering HTNV and SEOV has been available since the 1990s and is provided free in endemic areas. Crucially, no vaccine exists for Andes virus or other HPS-causing hantaviruses — making serological diagnosis and outbreak containment the only tools available when ANDV is implicated.
References
- World Health Organization. Disease Outbreak News: Hantavirus cluster linked to cruise ship travel — Multi-country. DON599. Published May 4, 2026.
- Mir MA. Hantaviruses. Clin Lab Med. 2010;30(1):67–91. doi:10.1016/j.cll.2010.01.004
- Martínez VP, Di Paola N, Alonso DO, et al. "Super-Spreaders" and Person-to-Person Transmission of Andes Virus in Argentina. N Engl J Med. 2020;383(23):2230–2241. doi:10.1056/NEJMoa2009040
- Jonsson CB, Figueiredo LT, Vapalahti O. A Global Perspective on Hantavirus Ecology, Epidemiology, and Disease. Clin Microbiol Rev. 2010;23(2):412–441.
- Xu Z, Li W, et al. Hantavirus infections in China: epidemiology, diagnosis and treatment. Emerg Microbes Infect. 2023.
- National Health Commission of China. 2024 Statistical Bulletin on the Development of Health Undertakings in China. December 2025.
- Astorga F, et al. Hantavirus in rodents in the United States: Temporal and spatial trends and report of new hosts. Ecosphere. 2025. doi:10.1002/ecs2.70209